EPICS: Global Perspectives in Lung Cancer in 2022 and Beyond

Expert perspectives and strategic insights on the latest therapeutic developments and translational research coming out of ESMO and WCLC 2022 regarding lung cancer treatment.

September 19 and 21, 2022
Corey Langer MD Scientific Leader Faculty Chair Aptitude Health


Corey Langer, MD, FACP

University of Pennsylvania, Philadelphia, PA, USA

Faculty Members

Marina Chiara Garassino, MD
University of Chicago, IL, USA

Antoinette J. Wozniak, MD
University of Pittsburgh Medical Center, Pittsburgh, PA, USA

David Spigel, MD
Sarah Cannon Research Institute, Nashville, TN, USA

Natasha Leighl, MD
University of Toronto, ON, Canada

Paul Paik, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Mark Socinski, MD
AdventHealth Cancer Institute, Orlando, FL, USA

Egbert Smit, MD, PhD
The Netherlands Cancer Institute, Amsterdam

Solange Peters, MD, PhD
University Hospital of Lausanne, Switzerland

Luis Paz-Ares, MD, PhD
Hospital Universitario 12 Octubre, Madrid, Spain


Sample Report

Start discovering the insights

View Report


  • Perioperative Immunotherapy in Early-Stage NSCLC
  • SCLC, Mesothelioma, Second-Line NSCLC, and Beyond: Old and New Data
  • Frontline Immunotherapy in Metastatic NSCLC
  • Immunotherapy in Unresectable Stage III NSCLC
  • EGFR (Common Mutations): Resectable and Metastatic
  • EGFR (Less Common Mutations, Including Exon 20 Insertions)
  • Oncogenic Drivers: Mutations
  • Oncogenic Drivers: Fusions

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.